

**BROCK UNIVERSITY RESEARCH ETHICS BOARD**  
**Thursday February 16, 2023**  
**12:00 – 2:00 p.m.**  
**Teams**

**Minutes of the SREB Meeting**

**Attendance**

Alyssa Bax (non-voting)  
 Danny Tarulli  
 Ege Kamber  
 Linda Morrice  
 Lori Walker (non-voting)  
 Michael Owen

Michele Donnelly  
 Miya Narushima  
 Nicole Luke  
 Sadia Jahanzeb  
 Sandra Bosacki  
 Sarah Ciotti

**Regrets**

Dan Cui  
 Esther Stanley  
 Harriet Yeboah  
 Matt Kwan  
 Robert Steinbauer

<b>MINUTES</b>		
<b>ITEM</b>	<b>DISCUSSION</b>	<b>ACTION</b>
1	<p><b>Motion to approve Agenda</b></p> <ul style="list-style-type: none"> <li>• Approved</li> </ul> <p><b>Motion to approve January Minutes</b></p> <ul style="list-style-type: none"> <li>• Approved</li> </ul> <p><b>Motion to approve January Decision Report</b></p> <ul style="list-style-type: none"> <li>• Approved</li> </ul>	<p>Motion to approve: LM            Secoded: MD            All in favour</p> <p>Motion to approve: DT            Secoded: MD            All in favour</p> <p>Motion to approve: LM            Secoded: SC            All in favour</p>
2	<p><b>Discussion Items</b></p> <p><b>CTO Certification Update:</b></p> <ul style="list-style-type: none"> <li>• Clinical Trials Ontario (CTO) is a group that centralizes the review of regulated clinical trials in Ontario. We are not part of their group because Brock researchers don't currently conduct that type of research.</li> <li>• To become certified by CTO an institution must go through an assessment period/process.</li> <li>• Network of Networks (N2) and the Canadian Association of Research Ethics Boards (CAREB) have SOPs that were assessed according to Canadian and American standards.</li> <li>• Originally mostly medical/physical risks were assessed but as research evolved, behavioral and other risks were also assessed.</li> <li>• The ORE piloted checklist items for assessment by CTO (for non-clinical REBs) and now they would like us to pilot the certification process as well.</li> <li>• Representatives will come onto campus in May 2023 to speak to the office and chairs and review our files and procedures for different types of applications.</li> <li>• We see this as an educational opportunity for both the CTO and the ORE.</li> <li>• The ORE already has most documents in place; however they need to be organized better to allow for ease of use/access.</li> <li>• CTO are interested in our opinions as they are more clinically and medically minded. They don't want to exclude smaller, non-medical institutions from certification.</li> </ul>	

- This certification could allow for a more streamlined multijurisdictional review process as it may help different institutions to trust each other's reviews.
- There are other bodies who currently offer similar accreditation, but they require a fee. This CTO certification is free.
- Q: Does the CTO certification require our REB to report any incidents of non-compliance etc. to them?
- A: No, non-compliance would still be reported to the secretariate as normal.
- Comment: This should be seen as a chance to celebrate the work that we're already doing and establish the things we need to change.

#### **TCPS2 2022 Update Presentation:**

- The new TCPS2 2022 was released in January 2023.
- Multiple rounds of community consultation went into the listed changes.
- The TCPS is a live document so it will be revised again as research evolves.
- Presented changes include:
  - **Consent updates** (i.e., blanket consent, broad consent, separate consent, research data repository)
    - Broad consent requirements: TCPS2 Article 3.13
    - Evolving capacity and ongoing consent emphasis
    - Repository vs. biobank vs. research data repository
  - Creation of Repositories
    - Creation of a repository (review process needs clarification)
    - Shared responsibility
  - Questions:
  - Q1: Will we update the consent form template to include the new information? Who informs participants of risks?
  - A1: Can develop the templates with other REB administrations for applicability to all institutions. It is the researcher's responsibility to inform the participants of the risks.
  - Comment: Hopefully the secondary use of data protocols will still be followed even when data is from repositories.
  - **Multijurisdictional review of minimal risk research updates:**
    - REB responsibilities
    - New ethics review model
    - Official agreements
    - Legislation and policies
  - Which ways to streamline?
    - Avoid unnecessary duplication.
    - Documentation kept for the entire process.
    - Disagreements: the board of records has the final decision
    - CTO has streamlined this process for health-related research (member process).
    - Some areas require further clarification, and the board will be updated at a future meeting.
  - **Review of research involving human cell lines updates:**
    - Cell lines and subcultures.
    - Re-use or secondary use
    - Deidentified human biological materials

		<ul style="list-style-type: none"> <li>▪ Exempt from REB review.</li> <li>▪ HeLa cell line description</li> </ul> <p><b>Synto question period and brief demonstration (if needed):</b></p> <ul style="list-style-type: none"> <li>• No questions/comments were brought up by SREB members.</li> <li>• Agreed to keep Synto on the agenda for the upcoming SREB meetings to continually check if there are any questions/issues.</li> <li>• It was decided that the meeting would adjourn, and Alyssa and Lori would stay online for those who missed the last meeting and wanted a demo or had any questions.</li> </ul> <p><b>Other Business</b></p> <ul style="list-style-type: none"> <li>• n/a</li> </ul>	
3	<b>Adjourn</b>	<b>Meeting adjourned at 1:13 p.m.</b>	Motion to approve: MD Seconded: MO All in favour